Calvin Chan

Calvin Chan

Auto-generated profile, based on publicly available information

Calvin Chan

Te Whatu Ora Health NZ Te Pae Hauora o Ruahine o Tararua MidCentral Palmerston North New Zealand

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 July 2019 in Headache: The Journal of Head and Face Pain
Verified
Journal Article
Closed access
DMDavid Moreno-Ajona
David Moreno-Ajona
CCCalvin Chan
Calvin Chan
MVMaría Dolores Villar‐Martínez
María Dolores Villar‐Martínez
Peter GoadsbyPeter Goadsby
Peter Goadsby

25 September 2019 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
CCCalvin Chan
Calvin Chan
Peter GoadsbyPeter Goadsby
Peter Goadsby

1 December 2019 in Journal of Neuro-Ophthalmology
Verified
Journal Article
Closed access
CCCalvin Chan
Calvin Chan
DWDiana Y. Wei
Diana Y. Wei
Peter GoadsbyPeter Goadsby
Peter Goadsby
Background: Migraine is a common disabling neurological disorder where attacks have been recognized to consist of more than headache. The premonitory, headache, and postdromal phases are the various phases of the migraine cycle, where aura can occur before, during, or after the onset of pain. Migraine is also associated with photosensitivity and cranial autonomic symptoms, which includes lacrimation, conjunctival injection, periorbital edema, ptosis, nasal congestion, and rhinorrhoea. This review will present the current understanding of migraine pathophysiology and the relationship to the observed symptoms. Evidence Acquisition: The literature was reviewed with specific focus on clinical, neurophysiological, functional imaging, and preclinical studies in migraine including the studies on the role of calcitonin gene-related peptide (CGRP) and pituitary adenylate cyclase activating polypeptide (PACAP). Results: The phases of the migraine cycle have been delineated by several studies. The observations of clinical symptoms help develop hypotheses of the key structures involved and the biochemical and neuronal pathways through which the effects are mediated. Preclinical studies and functional imaging studies have provided evidence for the role of multiple cortical areas, the diencephalon, especially the hypothalamus, and certain brainstem nuclei in the modulation of nociceptive processing, symptoms of the premonitory phase, aura, and photophobia. CGRP and PACAP have been found to be involved in nociceptive modulation and through exploration of CGRP mechanisms, new successful treatments have been developed. Conclusions: Migraine is a complex neural disorder and is important to understand when seeing patients who present to neuro-ophthalmology, especially with the successful translation from preclinical and clinical research leading to successful advances in migraine management.

28 April 2020 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
CCCalvin Chan
Calvin Chan
Peter GoadsbyPeter Goadsby
Peter Goadsby
Introduction Current treatment options for the prevention of cluster headache are largely unsatisfactory. The therapies have a limited evidence base and often significant side effects issues. The involvement of the calcitonin gene-related peptide (CGRP) pathway in primary headache disorders, especially migraine, had led to recent success in the development of new migraine therapies. The CGRP pathway also plays a role in the pathophysiology of cluster headache, so CGRP pathway monoclonal antibodies have been studied in the prevention of cluster headache attacks. Areas covered This review will outline the trials of fremanezumab and galcanezumab, the only two CGRP pathway monoclonal antibodies that have undergone trials in cluster headache prevention thus far. This review will highlight key efficacy and safety outcomes from the trials. Expert opinion Galcanezumab was shown to be efficacious in reducing the frequency of attacks in episodic cluster headache, while fremanezumab failed its primary endpoint in episodic cluster headache. Both fremanezumab and galcanezumab trials in chronic cluster headache were terminated after futility analysis predicting failure of both trials to fulfil their primary endpoint. The role of CGRP in cluster headache supports ongoing trials of the remaining CGRP pathway monoclonal antibodies and gepants for preventive and acute treatment. A Panglossian view would include targeting neuropeptides involved in parasympathetic signalling in cluster headache, such as pituitary adenylate cyclase-activating peptide (PACAP); such targets warrant exploration in the search of new cluster headache treatments.

23 March 2020 in Current Opinion in Neurology
Verified
Journal Article
Closed access
MVMaria Dolores Villar-Martinez
Maria Dolores Villar-Martinez
CCCalvin Chan
Calvin Chan
Peter GoadsbyPeter Goadsby
Peter Goadsby
Purpose of review: Cluster headache is a neurological disorder that patients consider the most severe pain they experience. Recognizing new treatments provides opportunities to advance current management. Recent findings: In contrast to the classic treatments, new options narrow in on the therapeutic target and are better tolerated. Calcitonin gene-related peptide (CGRP) pathway blockade with monoclonal antibodies (MABs), specifically the CGRP MAB galcanezumab, represents an important advance for episodic cluster headache, reducing the number of attacks during a bout. Neuromodulation strategies aimed at anatomical structures involved in the pathophysiology of cluster headache, such as the sphenopalatine ganglion and the vagus nerve, have proved effective in reducing the pain intensity and the number of attacks, and also to be safe and well tolerated. Summary: Our understanding of the pathophysiology of cluster headache and its management continues to grow. Novel treatments have appeared from research, such as neuromodulation and CGRP monoclonal antibodies. Nonetheless, chronic cluster headache and designing trials that select the correct sham in evaluating devices remain challenging.

1 January 2022
Verified
Book Chapter
Closed access
DMDavid Moreno-Ajona
David Moreno-Ajona
MMMaría Dolores Villar Martínez
María Dolores Villar Martínez
CCCalvin Chan
Calvin Chan
Peter GoadsbyPeter Goadsby
Peter Goadsby